4D Molecular Therapeutics filings document financial results, clinical-development disclosures and governance matters for a Nasdaq-listed biotechnology issuer. Form 8-K reports furnish quarterly and annual results and include pipeline updates for 4D-150, the 4FRONT program in wet AMD, and related PRISM and SPECTRA studies in retinal disease.
The company’s proxy materials cover director elections, auditor ratification and executive-compensation votes. Other filings disclose officer appointments and compensatory arrangements, equity awards, registered common stock, and capital-structure actions involving exchanges of common stock for pre-funded warrants with exercise limitations and beneficial-ownership blockers.
4D Molecular Therapeutics director Glenn Sblendorio reported a grant of stock options in the company. On January 5, 2026, he received 45,000 stock options to buy common shares at an exercise price of $7.30 per share. These options expire on January 4, 2036.
One-third of the options vest on the first anniversary of January 5, 2026, and the remaining two-thirds vest in equal monthly installments over the following two years. After this grant, Sblendorio beneficially owned 45,000 derivative securities directly.
4D Molecular Therapeutics director Glenn Sblendorio reported initial beneficial ownership of a stock option covering 11,250 shares of the company’s common stock at an exercise price of $2.76 per share. The option was granted on April 9, 2025 and vests over three years: one-third of the shares vest on the first anniversary of that date, with the remaining two-thirds vesting in equal monthly installments over the following two years, so that all 11,250 shares are fully vested and exercisable on the third anniversary.
4D Molecular Therapeutics reported a preliminary estimate of approximately $514 million in cash, cash equivalents and marketable securities as of December 31, 2025, noting this figure is unaudited and may change once year-end closing procedures are complete. The company also announced that President and Chief Operating Officer Fariborz Kamal, Ph.D., resigned from those roles on December 31, 2025 to pursue other opportunities, and moved to a part-time position as Chief Technical Advisor, with no disagreements cited regarding operations or strategy.
Effective January 1, 2026, Chief Executive Officer David Kirn, M.D., was also appointed President. In addition, effective January 5, 2026, the Board appointed Glenn Sblendorio as a Class I director and member of the Compensation and Science and Technology Committees, granting him an initial option to purchase 45,000 shares at an exercise price of $7.30 per share and cash retainers consistent with the company’s non-employee director compensation program.
4D Molecular Therapeutics director Charles Theuer reported exercising a stock option for 9,333 shares of common stock at $1.14 per share on December 12, 2025. The transaction is shown as an acquisition of common stock following the exercise of a fully vested stock option originally granting the right to buy 9,333 shares at $1.14, with an expiration date of March 9, 2026. After this transaction, Theuer directly beneficially owned 41,684 shares of 4D Molecular Therapeutics common stock and held no remaining derivative securities from this option grant.
4D Molecular Therapeutics, Inc. reported an equity award for its Chief Financial Officer. The officer received a stock option covering 480,000 shares of common stock at an exercise price of $10.51 per share, dated 12/09/2025, with the option expiring on 12/08/2035.
According to the vesting terms, 25% of the shares subject to the option vest on the first anniversary of the November 17, 2025 vesting commencement date. The remaining shares vest in 36 equal monthly installments so that the option is fully vested on the fourth anniversary of that date, provided the officer continues as a service provider to the company.
4D Molecular Therapeutics, Inc. reported that its Chief Financial Officer, Kristian Humer, had no beneficial ownership of the company’s securities as of December 9, 2025. The Section 16(a) insider ownership report indicates that no non-derivative or derivative securities of 4D Molecular Therapeutics are beneficially owned, and the filing was made for one reporting person.
4D Molecular Therapeutics, Inc. (FDMT) reported an insider equity transaction by its Chief Legal Officer on a Form 4. On 11/17/2025, the officer exercised a stock option to buy 1,635 shares of common stock at $4.14 per share and, on the same date, sold 1,635 shares at $10.59 per share under a Rule 10b5-1 trading plan adopted on June 6, 2025. After these trades, the officer directly holds 3,594 shares of common stock and 75,230 stock options. The option underlying this transaction covers 1,635 shares and vests in equal monthly installments over four years starting from March 6, 2025, as long as the officer continues to serve the company.
4D Molecular Therapeutics, Inc. (FDMT) appointed Kristian Humer as its new Chief Financial Officer and Principal Financial Officer effective November 17, 2025. Humer brings experience from senior finance roles at Foghorn Therapeutics, Viridian Therapeutics, and Citigroup’s healthcare investment banking group. Under his offer letter, he receives an annual base salary of $520,000, a target annual bonus equal to 40% of base salary, a stock option to purchase 480,000 shares of common stock, and a $100,000 sign-on bonus paid in two installments with multi-year earn-out conditions tied to continued employment. If he is terminated without cause or resigns for good reason, he is eligible for severance benefits, including salary continuation and COBRA premium reimbursement, with enhanced benefits and full vesting acceleration of equity awards if such a termination occurs within 12 months after a change in control.
4D Molecular Therapeutics (FDMT) reported a larger quarterly loss as R&D spending increased. For the three months ended September 30, 2025, revenue was $90 thousand, research and development expense was $49.4 million, and general and administrative expense was $11.8 million, leading to a net loss of $56.9 million and a basic and diluted net loss per share of $1.01.
Liquidity remained solid with cash, cash equivalents and marketable securities totaling $372.2 million as of September 30, 2025. Net cash used in operating activities was $137.6 million for the nine months ended September 30, 2025. The company states these resources are sufficient to fund planned operations for at least one year from the financial statement issuance date.
As a subsequent event, in November 2025 FDMT completed an underwritten offering with net proceeds of approximately $93.3 million. As of November 7, 2025, shares outstanding were 57,135,075; an additional 10,513,949 shares were issuable upon exercise of pre-funded warrants at $0.0001 per share, subject to beneficial ownership limitations.
4D Molecular Therapeutics, Inc. filed a current report to note that it has released its financial results for the three months ended September 30, 2025. The company furnished a press release titled “4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones” as Exhibit 99.1. The filing indicates that the release also covers recent operational developments and outlines milestones the company expects in the future.